Procter & Gamble Health Ltd. primarily deals with both manufacturing and marketing various chemicals and pharmaceuticals. Financial Results: Procter & Gamble Health
Procter & Gamble Health Q2FY23 Earnings Story
Procter & Gamble Health Ltd. primarily deals with both manufacturing and marketing various chemicals and pharmaceuticals. Financial Results: Procter & Gamble Health
A pharmaceutical firm with a strong focus on research and development, NATCO Pharma Ltd creates, produces, and markets sophisticated pharmaceuticals for specialised
Pfizer Ltd is primarily involved in marketing, exporting, manufacturing, and trading of pharmaceutical products. It produces goods through its in-house facility and
Panacea Biotec Limited’s revenue in Q3FY23 fell 26% to ₹ 11,520 lakhs. Consolidated Profit After Tax came at ₹ 1,937 lakhs in
Lupin Ltd (NSE:LUPIN) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Vinita Gupta -- Chief Executive Officer Ramesh Swaminathan -- Executive Director, Global Chief
Lupin Limited’s revenue in Q3FY23 rose 13% to ₹ 1,97,66,301 lakhs. Consolidated Profit After Tax came at ₹ 8,34,871 lakhs in Q3FY23
Sun Pharmaceutical Industries Limited’s revenue in Q3FY23 rose 14% to ₹ 112,410 millions. Consolidated Profit After Tax came at ₹ 21,808 millions
Aurobindo Pharma Ltd.‘s revenue in Q2FY23 fell 3% to ₹ 5,739 crores. Consolidated Profit came at ₹ 409 crores showcasing a 41%
Divi's Laboratories Ltd.'s revenues in Q2FY23 fell 7% to ₹ 1,855 crores. Consolidated Profit came at ₹ 494 crores showcasing a 19%
Torrent Pharmaceuticals Ltd.‘s Revenues for Q2 FY23 has increased by 7% YoY to ₹ 2,291 crores. Net Profit fell by 1% YoY
Revenue for Q1 FY23 has increased by 1% YoY to ₹ 37,956 millions. Profits have fallen by 35% YoY to ₹ 31,711
Revenue for Q1 FY23 has increased by 9% YoY to ₹ 6,235.9 crores. Profits have fallen by 32% YoY to ₹ 520.5
Revenue for Q1 FY23 has increased by 1.8% YoY to ₹40,727 millions. Profits decreased by 12% YoY to ₹5,183 millions because Total
Revenue for Q1 FY23 has increased by 22% YoY to ₹ 3,548 crores. Profits have fallen by 8% YoY to ₹ 496.09
Revenue for Q1 FY23 has increased by 6% YoY to ₹ 52,154 millions. Profits have grown by 108% YoY to ₹ 11,876